The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Pfizer and Johnson & Johnson are two healthcare giants. Both have a solid earnings growth outlook, but they differ in terms of valuation, as well as in the dividend yields they offer right here.

Johnson & Johnson sought help from its three rival Covid-19 vaccine makers to look into reports of blood clots, but Pfizer and Moderna both declined, the Wall Street Journal reported on Friday ...

Johnson & Johnson expects to make $2.5 billion in revenue from its COVID-19 vaccine in 2021. That's a drop in the bucket for the mammoth business, which generated more than $80 billion in revenue ...

Some consumers have been wary of the Johnson & Johnson vaccine because its overall efficacy in clinical trials was 66% compared with about 95% for the Moderna and Pfizer vaccines.

The Pfizer vaccine is the first to receive FDA approval, while the Moderna and Johnson & Johnson vaccines are available under an emergency use authorization. For children ages 12 to 15 , Pfizer's ...

While the Pfizer and Moderna shots have a lot in common, the new Johnson & Johnson vaccine has some notable differences. A fourth COVID-19 inoculation, the AstraZeneca vaccine, may also soon be ...

CDC recommends Pfizer, Moderna vaccines over Johnson & Johnson, citing rare blood-clot issue Nine deaths, several dozen cases, have been confirmed in connection with the vaccine. Updated December ...